{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.96","upperLimit":"34.56","value":"30.98"},{"groupId":"OG001","lowerLimit":"22.57","upperLimit":"33.08","value":"26.55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"485"},{"groupId":"OG001","value":"239"}],"units":"Participants"}],"description":"Overall survival, the key secondary endpoint in this study, is defined as the time from date of randomization to the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Everolimus 10 mg daily in combination with exemestane 25 mg daily","id":"OG000","title":"Everolimus + Exemestane"},{"description":"Placebo of everolimus in combination with exemestane 25 mg daily","id":"OG001","title":"Placebo + Exemestane"}],"paramType":"MEDIAN","populationDescription":"All randomized patients were included in the Full Analysis Set.","reportingStatus":"POSTED","timeFrame":"up to 53 months","title":"Overall Survival (OS) by Median","type":"SECONDARY","unitOfMeasure":"Months"}